Evidence map›Paper›PMID 41748695›Full record

ArticleLeukemia2026

Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.

Jonas S Jutzi, Edie Crosse, Chulwoo J Kim, Bob van Gasteren, Charles Laurore, Benjamin Rolles, Frederike Kramer, Anastasia Tishena, Azucena V Rocha, Mohammed Wazir and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jonas S JutziDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1977-153X
Edie CrosseBasic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Chulwoo J KimDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Bob van GasterenLaboratory of Hematology, Department of Laboratory Medicine, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, the Netherlands.
Charles LauroreDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Benjamin RollesDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7393-861X
Frederike KramerDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Anastasia TishenaDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Azucena V RochaDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Mohammed WazirDivision of General Internal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Lachelle D WeeksCenter for Prevention of Progression, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-8726-6212
Joan HowDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-6421-0117
Maximilian StahlDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Marlise R LuskinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-5781-4529
R Coleman LindsleyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9822-806X
Olga PozdnyakovaDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0001-8376-0344
Sumit RaiMassachusetts General Hospital Cancer Center, Charlestown, MA, USA.
Timothy A GraubertMassachusetts General Hospital Cancer Center, Charlestown, MA, USA.
Robert K BradleyBasic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-8046-1063
Ann MullallyDivision of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Anna E MarnethDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Anna.Marneth@radboudumc.nl.ORCID 0000-0001-9065-0581

Funding

Functional and Molecular Dissection of Mutant Calreticulin in Myeloproliferative NeoplasmsR01HL131835 · NHLBI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI Ann Mullally · 2016 to 2026
$4.1M
Deutsche Krebshilfe (German Cancer Aid) 70114570Radboud Universitair Medisch Centrum (Radboudumc) HypatiaStarr Foundation I15-0026U.S. Department of Defense (United States Department of Defense) W81XWH-20-1-0904U.S. Department of Defense (United States Department of Defense) W81XWH2110909U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL131835
6 · The paper itself

Abstract

Somatic mutations in RNA splicing regulators, including the serine/arginine-rich protein SRSF2, are frequently observed in myeloid malignancies. Using mouse models and primary human samples, we investigated the impact of SRSF2 mutations on erythropoiesis. We found reduced erythropoiesis in Srsf2

Indexed as

ErythropoiesisMechanistic Target of Rapamycin Complex 1MutationMyeloproliferative DisordersProto-Oncogene Proteins c-fynRNA SplicingSerine-Arginine Splicing FactorsAnimalsHumansMiceSignal TransductionFYN protein, humanMechanistic Target of Rapamycin Complex 1Proto-Oncogene Proteins c-fynSerine-Arginine Splicing FactorsSRSF2 protein, humanSRSF2 protein, mouse

Identifiers

PMID41748695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.